title: [Diagnosis and therapy of sepsis: guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine].
abstract: A recent survey conducted by the publicly funded Competence Network Sepsis (SepNet) reveals that severe sepsis and/or septic shock occurs in 75,000 inhabitants (110 out of 100,000) and sepsis in 79,000 inhabitants (116 out of 100,000) in Germany annually. This illness is responsible for approximately 60,000 deaths and ranges as the third most frequent cause of death after acute myocardial infarction. Direct costs for the intensive care of patients with severe sepsis alone amount to approximately 1.77 billion euros, which means that about 30% of the budget in intensive care is used to treat severe sepsis. However, until now German guidelines for the diagnosis and therapy of severe sepsis did not exist. Therefore, the German Sepsis Society initiated the development of guidelines which are based on international recommendations by the International Sepsis Forum (ISF) and the Surviving Sepsis Campaign (SSC) and take into account the structure and organization of the German health care system. Priority was given to the following guideline topics: a) diagnosis, b) prevention, c) causative therapy, d) supportive therapy, e) adjunctive therapy. The guidelines development process was carefully planned and strictly adhered to the requirements of the Working Group of Scientific Medical Societies (AWMF).
authors.affiliation: Deutsche Sepsis-Gesellschaft e V c/o Universitatsklinikum Jena, Erlanger Allee 101, 07747 Jena.
authors.forename: K
authors.initials: K
authors.lastname: Reinhart
authors.forename: F
authors.initials: F
authors.lastname: Brunkhorst
authors.forename: H
authors.initials: H
authors.lastname: Bone
authors.forename: H
authors.initials: H
authors.lastname: Gerlach
authors.forename: M
authors.initials: M
authors.lastname: Gründling
authors.forename: G
authors.initials: G
authors.lastname: Kreymann
authors.forename: P
authors.initials: P
authors.lastname: Kujath
authors.forename: G
authors.initials: G
authors.lastname: Marggraf
authors.forename: K
authors.initials: K
authors.lastname: Mayer
authors.forename: A
authors.initials: A
authors.lastname: Meier-Hellmann
authors.forename: C
authors.initials: C
authors.lastname: Peckelsen
authors.forename: C
authors.initials: C
authors.lastname: Putensen
authors.forename: M
authors.initials: M
authors.lastname: Quintel
authors.forename: M
authors.initials: M
authors.lastname: Ragaller
authors.forename: R
authors.initials: R
authors.lastname: Rossaint
authors.forename: F
authors.initials: F
authors.lastname: Stüber
authors.forename: N
authors.initials: N
authors.lastname: Weiler
authors.forename: T
authors.initials: T
authors.lastname: Welte
authors.forename: K
authors.initials: K
authors.lastname: Werdan
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D005858:Germany; D006801:Humans; D008020:Life Support Care; D009747:Nutritional Physiological Phenomena; D011014:Pneumonia / Q000209:etiology; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D012121:Respiration, Artificial / Q000009:adverse effects / Q000295:instrumentation; D012138:Respiratory Therapy; D018805:Sepsis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D012772:Shock, Septic / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents